OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of RMB 200 million (USD 27.8 million) in a pre-IPO financing round. The round was led by CCB Private Equity Investment and Huajin Capital, with participation from Guoxin Capital and Befor Capital. The funds will be utilized to enhance product industrialization, expand the global marketing network and channel, and solidify OptoMedic’s comprehensive competitive advantages in the endoscopy field.
OptoMedic’s Core Technologies and Product Pipeline
Founded in 2013, OptoMedic has established itself with several core technologies, including minimally invasive visual technology, an intelligent imaging platform, and advanced mirror body design and processing technology. The company’s product pipeline encompasses a range of endoscopy systems, both hard and soft, as well as supporting equipment and developers. OptoMedic made a significant impact in the domestic market by launching the first high-definition fluorescent endoscope system in 2018 and further solidified its position with the introduction of the first 4K fluorescent endoscope system in China in 2020.
Innovative Endoscopy Platforms and Global Reach
In 2022, OptoMedic launched Stellar, a fully functional endoscope platform that integrates fluorescence imaging, 3D imaging, and 4K functions, demonstrating the company’s commitment to innovation and technological advancement in endoscopy. With this pre-IPO funding, OptoMedic is poised to strengthen its global presence and continue to lead in the development of cutting-edge endoscopy solutions.-Fineline Info & Tech
